• Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation
• Case report: The success of empagliflozin therapy for glycogen storage disease type 1b
• Clinical characteristics and long-term outcomes of patients with glycogen storage disease type 1b: a retrospective multi-center experience in Poland
• Clinical Remission of Severe Crohn's Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
• Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b
• Dental rehabilitation in a young patient with glycogen storage disease type 1B
• Elucidation of intermolecular interactions between chlorogenic acid and glucose-6-phosphate translocase: A step towards chemically induced glycogen storage disease type 1b model
• Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b
• Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients
• Glycogen Storage Disease Type I
• Glycogen Storage Disease Type I
• Identification of mutations that causes glucose-6-phosphate transporter defect in tunisian patients with glycogenosis type 1b
• Immune dysregulation in Glycogen Storage Disease 1b - a CyTOF approach
• Immunological features and complications in patients with glycogen storage disease 1b after living donor liver transplantation
• Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort
• LONG TERM MANAGEMENT OF GLYCOGEN STORAGE DISEASE TYPE 1B: A BRAZILIAN TERTIARY CENTER EXPERIENCE
• Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin
• Peristomal cellulitis following percutaneous endoscopic gastrostomy tube placement in glycogen storage disease type 1b
• Rare complication of inflammatory bowel disease-like colitis from glycogen storage disease type 1b and its surgical management: A case report
• SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia
• Sodium-glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?
• Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5
• The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb
• Three novel SLC37A4 variants in glycogen storage disease type 1b and a literature review
• Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop